Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCESS 2: Sirolimus eluting Collagen Implant for AV Fistula Outcomes
NCT05425056Phase 3Completed
- Sponsor
- Vascular Therapies
- Start
- Aug 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, single-blind trial of sirolimus in vascular access complication (2 arms), sponsored by Vascular Therapies. Primary endpoint: Clinical Fistula Maturation at 6 months. Started Aug 2022; status: completed.
02
Drugs
sirolimus
03
Conditions
vascular access complication
Beyond the preview
Go deeper on NCT05425056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05425056.